Abstract
Pancreatic cancer is a uniformly lethal disease that is difficult to diagnose at early stage and even more difficult to cure. In recent years, there has been a substantial interest in applying proteomics technologies to identify protein biomarkers for early detection of cancer. Quantitative proteomic profiling of body fluids, tissues, or other biological samples to identify differentially expressed proteins represents a very promising approach for improving the outcome of this disease. Proteins associated with pancreatic cancer identified through proteomic profiling technologies could be useful as biomarkers for the early diagnosis, therapeutic targets, and disease response markers. In this article, we discuss recent progress and challenges for applying quantitative proteomics technologies for biomarker discovery in pancreatic cancer.
Highlights
Pancreatic cancer is a uniformly lethal disease that is difficult to diagnose at early stage and even more difficult to cure
What biological specimens should be used in the search for the biomarkers? Several types of specimens are available for pancreatic cancer research, including pancreatic tissue, proximal body fluid such as pancreatic juice, and accessible body fluids such as serum or plasma
Pancreatic ductal adenocarcinoma consists of a solid mass with 30 –90% of tumor cells interspersed with a fibroblastic stroma
Summary
Pancreatic cancer is a uniformly lethal disease that is difficult to diagnose at early stage and even more difficult to cure. There has been a substantial interest in applying proteomics technologies to identify protein biomarkers for early detection of cancer. Quantitative proteomic profiling of body fluids, tissues, or other biological samples to identify differentially expressed proteins represents a very promising approach for improving the outcome of this disease. Proteins associated with pancreatic cancer identified through proteomic profiling technologies could be useful as biomarkers for the early diagnosis, therapeutic targets, and disease response markers. Recent proteomics studies in pancreatic cancer have identified proteins differentially regulated in cancer samples and have led to the discovery of several candidate biomarkers (12).. The use of proteomic profiling for pancreatic cancer biomarker discovery is still at its early stage; the efforts so far have been productive and the results are encouraging.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
